Business
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
BOSTON,, September 26, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its previously announced underwritten public offering of 35,937,500 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 4,687,500 additional shares, at the public off
About this update from Pepgen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/16323555b1ebc140656f04327143f3ce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Je1eoxNofuyfxGa5n6DT2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/16323555b1ebc140656f04327143f3ce","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.Ol5X8O0X95XJDkQRGcijw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/16323555b1ebc140656f04327143f3ce","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOSTON,, September 26, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its previously announced underwritten public offering of 35,937,500 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 4,687,500 additional shares, at the public offering price of $3.20 per share. The aggregate gross proceeds to PepGen from this offering, before deducting underwriting discounts and commissions and offering expenses, were $115 million.","length":705,"tagName":"p"},{"type":"text","content":"Leerink Partners and Stifel acted as joint bookrunning managers for the offering.","length":81,"tagName":"p"},{"type":"text","content":"PepGen intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.","length":249,"tagName":"p"},{"type":"text","content":"The shares were offered pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (SEC) on July 8, 2024. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on September 25, 2025 and are available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompany...